JPMorgan Recommends Buying Apellis and Live Oak Stocks, Sees Upside Potential Despite Market Volatility

J.P. Morgan strategist sees good value in the market during recent volatility caused by rising Treasury yields. Recommends two stocks to buy.

Apellis Pharmaceuticals has two newly approved complement system drugs, including potential $3B blockbuster Syfovre for retinal disease.

Live Oak Bancshares is the nation's largest SBA lender. Stock pulled back recently, presenting a buying opportunity per JPMorgan analyst.

Apellis has 82% upside potential while Live Oak is expected to gain 37%, according to JPMorgan's price targets.

Analysts optimistic on both stocks, with Strong Buy rating for Apellis and Moderate Buy for Live Oak.